Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25,530 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mechano-regulation of Peptide-MHC Class I Conformations Determines TCR Antigen Recognition.
Wu P, Zhang T, Liu B, Fei P, Cui L, Qin R, Zhu H, Yao D, Martinez RJ, Hu W, An C, Zhang Y, Liu J, Shi J, Fan J, Yin W, Sun J, Zhou C, Zeng X, Xu C, Wang J, Evavold BD, Zhu C, Chen W, Lou J. Wu P, et al. Among authors: shi j. Mol Cell. 2019 Mar 7;73(5):1015-1027.e7. doi: 10.1016/j.molcel.2018.12.018. Epub 2019 Jan 30. Mol Cell. 2019. PMID: 30711376 Free PMC article.
Mathematical models of TCR initial triggering.
Shi J, Yin W, Chen W. Shi J, et al. Front Immunol. 2024 Jul 18;15:1411614. doi: 10.3389/fimmu.2024.1411614. eCollection 2024. Front Immunol. 2024. PMID: 39091495 Free PMC article. Review.
Clonal GZMK+CD8+ T cells are identified as a hallmark of the pathogenesis of cGVHD-induced bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
Gao Y, Liu R, Shi J, Shan W, Zhou H, Chen Z, Yue X, Zhang J, Luo Y, Pan W, Zhao X, Zeng X, Yin W, Xiao H. Gao Y, et al. Among authors: shi j. EBioMedicine. 2024 Dec 30;112:105535. doi: 10.1016/j.ebiom.2024.105535. Online ahead of print. EBioMedicine. 2024. PMID: 39740295 Free article.
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer.
Chen Z, Chen J, Huang D, Zhang W, Wu L, Yi T, Wang Q, Han L, Tan L, Li Y, Zhang Z, Li N, Li J, Zhang T, Hu Y, Sun H, Wu Y, He Z, Yang R, Cheng P, Li X, Shi J, Yu G, Ma D, Li BX, Dai X, Wong M, Li Y, Yu X, Lu S; Socazolimab Study Group. Chen Z, et al. Among authors: shi j. Signal Transduct Target Ther. 2025 Jan 13;10(1):28. doi: 10.1038/s41392-024-02115-5. Signal Transduct Target Ther. 2025. PMID: 39800716 Clinical Trial.
Long-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase Ⅱ YH-S001-04 clinical trial.
Kan S, Bai H, Liu H, Cui J, Ke X, Zhang H, Liu L, Yan D, Jiang Y, Zang A, Qi J, Wang L, Liu Z, Xu B, Zhang Y, Zhang Z, Zhao X, Hu C, Yang S, Zhou H, Shi J, Shao Z, Xiang Y, Lin N, Zhang M. Kan S, et al. Among authors: shi j. Leuk Res. 2024 Nov 26;149:107633. doi: 10.1016/j.leukres.2024.107633. Online ahead of print. Leuk Res. 2024. PMID: 39799811
25,530 results
You have reached the last available page of results. Please see the User Guide for more information.